96 related articles for article (PubMed ID: 32466836)
1. Use of the Win Ratio in Cardiovascular Trials.
Ferreira JP; Jhund PS; Duarte K; Claggett BL; Solomon SD; Pocock S; Petrie MC; Zannad F; McMurray JJV
JACC Heart Fail; 2020 Jun; 8(6):441-450. PubMed ID: 32466836
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
Selvaraj S; Claggett B; Pozzi A; McMurray JJV; Jhund PS; Packer M; Desai AS; Lewis EF; Vaduganathan M; Lefkowitz MP; Rouleau JL; Shi VC; Zile MR; Swedberg K; Solomon SD
Circulation; 2019 Oct; 140(17):1369-1379. PubMed ID: 31510768
[TBL] [Abstract][Full Text] [Related]
3. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
Shen L; Ramires F; Martinez F; Bodanese LC; Echeverría LE; Gómez EA; Abraham WT; Dickstein K; Køber L; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Jhund PS; Gimpelewicz CR; McMurray JJV;
Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141857
[TBL] [Abstract][Full Text] [Related]
6. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
7. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?
Bangalore S; Kumar S; Messerli FH
Congest Heart Fail; 2013; 19(3):107-15. PubMed ID: 23241032
[TBL] [Abstract][Full Text] [Related]
8. Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits.
Shen L; Jhund PS; Mogensen UM; Køber L; Claggett B; Rogers JK; McMurray JJV
JACC Heart Fail; 2017 Aug; 5(8):591-599. PubMed ID: 28774394
[TBL] [Abstract][Full Text] [Related]
9. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
Docherty KF; McMurray JJV
Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
Corbalan R; Bassand JP; Illingworth L; Ambrosio G; Camm AJ; Fitzmaurice DA; Fox KAA; Goldhaber SZ; Goto S; Haas S; Kayani G; Mantovani LG; Misselwitz F; Pieper KS; Turpie AGG; Verheugt FWA; Kakkar AK;
JAMA Cardiol; 2019 Jun; 4(6):526-548. PubMed ID: 31066873
[TBL] [Abstract][Full Text] [Related]
13. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Lesogor A; Cohn JN; Latini R; Tognoni G; Krum H; Massie B; Zalewski A; Kandra A; Hua TA; Gimpelewicz C
Eur J Heart Fail; 2013 Nov; 15(11):1236-44. PubMed ID: 23787721
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
[TBL] [Abstract][Full Text] [Related]
16. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
Savarese G; Dahlström U; Vasko P; Pitt B; Lund LH
Eur Heart J; 2018 Dec; 39(48):4257-4265. PubMed ID: 30351407
[TBL] [Abstract][Full Text] [Related]
17. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
19. Renin-Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study.
Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Manzano-Fernández S; Flores-Blanco P; Barreiro-Pardal C; Castiñeira-Busto M; Muñoz-Pousa I; López-Rodríguez E; Caneiro-Queija B; Cobas-Paz R; Fernández-Barbeira S; Domínguez-Erquicia P; Domínguez-Rodríguez LM; López-Cuenca Á; Gómez-Molina M; Baz-Alonso JA; Calvo-Iglesias F; Valdés-Chávarri M; Íñiguez-Romo A
Am J Cardiovasc Drugs; 2019 Oct; 19(5):487-495. PubMed ID: 30924021
[TBL] [Abstract][Full Text] [Related]
20. Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
Bernardez-Pereira S; Ramires FJA; de Melo RFT; Pereira-Barretto AC
Cardiol Rev; 2018; 26(4):196-200. PubMed ID: 29369824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
